| DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
| Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[19] |
| Ivosidenib |
DM8S6T7
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[20] |
| Midostaurin |
DMI6E0R
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[21] |
| Idarubicin |
DMM0XGL
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[21] |
| Daunorubicin |
DMQUSBT
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[21] |
| Oliceridine |
DM6MDCF
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Oliceridine. |
Acute pain [MG31]
|
[21] |
| Metronidazole |
DMTIVEN
|
Minor |
Increased risk of prolong QT interval by the combination of Flutamide and Metronidazole. |
Amoebiasis [1A36]
|
[19] |
| Ivabradine |
DM0L594
|
Major |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Ivabradine. |
Angina pectoris [BA40]
|
[21] |
| Bepridil |
DM0RKS4
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Bepridil. |
Angina pectoris [BA40]
|
[22] |
| Dronedarone |
DMA8FS5
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Dronedarone. |
Angina pectoris [BA40]
|
[22] |
| Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[23] |
| Hydroxyzine |
DMF8Y74
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Hydroxyzine. |
Anxiety disorder [6B00-6B0Z]
|
[21] |
| Cilostazol |
DMZMSCT
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Cilostazol. |
Arterial occlusive disease [BD40]
|
[21] |
| Voriconazole |
DMAOL2S
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Voriconazole. |
Aspergillosis [1F20]
|
[21] |
| Posaconazole |
DMUL5EW
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Posaconazole. |
Aspergillosis [1F20]
|
[21] |
| Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Levalbuterol. |
Asthma [CA23]
|
[24] |
| Terbutaline |
DMD4381
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Terbutaline. |
Asthma [CA23]
|
[25] |
| Pirbuterol |
DMI5678
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Pirbuterol. |
Asthma [CA23]
|
[25] |
| Salbutamol |
DMN9CWF
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Salbutamol. |
Asthma [CA23]
|
[24] |
| Formoterol |
DMSOURV
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Formoterol. |
Asthma [CA23]
|
[25] |
| Lisdexamfetamine |
DM6W8V5
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[21] |
| Desipramine |
DMT2FDC
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Desipramine. |
Attention deficit hyperactivity disorder [6A05]
|
[21] |
| Obeticholic acid |
DM3Q1SM
|
Moderate |
Decreased metabolism of Flutamide caused by Obeticholic acid mediated inhibition of CYP450 enzyme. |
Autoimmune liver disease [DB96]
|
[26] |
| Ofloxacin |
DM0VQN3
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Ciprofloxacin XR |
DM2NLS9
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ciprofloxacin XR. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Clarithromycin |
DM4M1SG
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Clarithromycin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Sulfamethoxazole |
DMB08GE
|
Minor |
Increased risk of prolong QT interval by the combination of Flutamide and Sulfamethoxazole. |
Bacterial infection [1A00-1C4Z]
|
[22] |
| Sparfloxacin |
DMB4HCT
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Sparfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[27] |
| Gemifloxacin |
DMHT34O
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Norfloxacin |
DMIZ6W2
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Levofloxacin |
DMS60RB
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Lomefloxacin |
DMVRH9C
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Lomefloxacin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Telithromycin |
DMZ4P3A
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Telithromycin. |
Bacterial infection [1A00-1C4Z]
|
[21] |
| Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Retigabine. |
Behcet disease [4A62]
|
[21] |
| Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Flutamide and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[28] |
| Loperamide |
DMOJZQ9
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Loperamide. |
Bowel habit change [ME05]
|
[29] |
| Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[21] |
| Tamoxifen |
DMLB0EZ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Tamoxifen. |
Breast cancer [2C60-2C6Y]
|
[21] |
| Toremifene |
DMQYUWG
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Toremifene. |
Breast cancer [2C60-2C6Y]
|
[22] |
| Bosutinib |
DMTI8YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[21] |
| PF-04449913 |
DMSB068
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[21] |
| Olodaterol |
DM62B78
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[25] |
| Vilanterol |
DMF5EK1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Vilanterol. |
Chronic obstructive pulmonary disease [CA22]
|
[24] |
| Salmeterol |
DMIEU69
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Salmeterol. |
Chronic obstructive pulmonary disease [CA22]
|
[25] |
| Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[25] |
| Arformoterol |
DMYM974
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[25] |
| Anisindione |
DM2C48U
|
Moderate |
Increased risk of bleeding by the combination of Flutamide and Anisindione. |
Coagulation defect [3B10]
|
[30] |
| Oxaliplatin |
DMQNWRD
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Oxaliplatin. |
Colorectal cancer [2B91]
|
[21] |
| Isoproterenol |
DMK7MEY
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Isoproterenol. |
Conduction disorder [BC63]
|
[24] |
| Halothane |
DM80OZ5
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Halothane. |
Corneal disease [9A76-9A78]
|
[21] |
| Propofol |
DMB4OLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Propofol. |
Corneal disease [9A76-9A78]
|
[31] |
| Sevoflurane |
DMC9O43
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Sevoflurane. |
Corneal disease [9A76-9A78]
|
[21] |
| Probucol |
DMVZQ2M
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Probucol. |
Coronary atherosclerosis [BA80]
|
[21] |
| Clofazimine |
DMEBOFW
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Clofazimine. |
Crohn disease [DD70]
|
[21] |
| Mifepristone |
DMGZQEF
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Mifepristone. |
Cushing syndrome [5A70]
|
[22] |
| Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Pasireotide. |
Cushing syndrome [5A70]
|
[22] |
| Osilodrostat |
DMIJC9X
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Osilodrostat. |
Cushing syndrome [5A70]
|
[21] |
| Sertraline |
DM0FB1J
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Sertraline. |
Depression [6A70-6A7Z]
|
[21] |
| Trimipramine |
DM1SC8M
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Trimipramine. |
Depression [6A70-6A7Z]
|
[21] |
| Nortriptyline |
DM4KDYJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Nortriptyline. |
Depression [6A70-6A7Z]
|
[21] |
| Escitalopram |
DMFK9HG
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Escitalopram. |
Depression [6A70-6A7Z]
|
[22] |
| Clomipramine |
DMINRKW
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Clomipramine. |
Depression [6A70-6A7Z]
|
[21] |
| Trazodone |
DMK1GBJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Trazodone. |
Depression [6A70-6A7Z]
|
[21] |
| Amoxapine |
DMKITQE
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Amoxapine. |
Depression [6A70-6A7Z]
|
[21] |
| Doxepin |
DMPI98T
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Doxepin. |
Depression [6A70-6A7Z]
|
[21] |
| Maprotiline |
DMPWB7T
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Maprotiline. |
Depression [6A70-6A7Z]
|
[21] |
| Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[21] |
| Deutetrabenazine |
DMUPFLI
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Deutetrabenazine. |
Dystonic disorder [8A02]
|
[21] |
| Ingrezza |
DMVPLNC
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ingrezza. |
Dystonic disorder [8A02]
|
[21] |
| Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[21] |
| Solifenacin |
DMG592Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Solifenacin. |
Functional bladder disorder [GC50]
|
[21] |
| Pentamidine |
DMHZJCG
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Pentamidine. |
Fungal infection [1F29-1F2F]
|
[21] |
| Ketoconazole |
DMPZI3Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[21] |
| Cisapride |
DMY7PED
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Cisapride. |
Gastro-oesophageal reflux disease [DA22]
|
[22] |
| Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[21] |
| Brentuximab vedotin |
DMWLC57
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[32] |
| Fostemsavir |
DM50ILT
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[21] |
| Efavirenz |
DMC0GSJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[33] |
| Saquinavir |
DMG814N
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Saquinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[34] |
| Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[21] |
| Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Flutamide and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[35] |
| Teriflunomide |
DMQ2FKJ
|
Major |
Increased risk of hepatotoxicity by the combination of Flutamide and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[22] |
| BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Flutamide and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[36] |
| Givosiran |
DM5PFIJ
|
Moderate |
Decreased metabolism of Flutamide caused by Givosiran mediated inhibition of CYP450 enzyme. |
Inborn porphyrin/heme metabolism error [5C58]
|
[37] |
| Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[21] |
| Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[22] |
| Methotrexate |
DM2TEOL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Methotrexate. |
Leukaemia [2A60-2B33]
|
[21] |
| Porfimer Sodium |
DM7ZWNY
|
Moderate |
Increased risk of photosensitivity reactions by the combination of Flutamide and Porfimer Sodium. |
Lung cancer [2C25]
|
[38] |
| Osimertinib |
DMRJLAT
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Osimertinib. |
Lung cancer [2C25]
|
[39] |
| Capmatinib |
DMYCXKL
|
Moderate |
Decreased metabolism of Flutamide caused by Capmatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[40] |
| Selpercatinib |
DMZR15V
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Selpercatinib. |
Lung cancer [2C25]
|
[21] |
| Lumefantrine |
DM29GAD
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Lumefantrine. |
Malaria [1F40-1F45]
|
[19] |
| Halofantrine |
DMOMK1V
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Halofantrine. |
Malaria [1F40-1F45]
|
[41] |
| Chloroquine |
DMSI5CB
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Chloroquine. |
Malaria [1F40-1F45]
|
[21] |
| Primaquine |
DMWQ16I
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Primaquine. |
Malaria [1F40-1F45]
|
[21] |
| Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[21] |
| Idelalisib |
DM602WT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[42] |
| Arsenic trioxide |
DM61TA4
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Arsenic trioxide. |
Mature B-cell lymphoma [2A85]
|
[43] |
| Clofarabine |
DMCVJ86
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[44] |
| Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Vemurafenib. |
Melanoma [2C30]
|
[22] |
| LGX818 |
DMNQXV8
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and LGX818. |
Melanoma [2C30]
|
[21] |
| Exjade |
DMHPRWG
|
Moderate |
Decreased metabolism of Flutamide caused by Exjade mediated inhibition of CYP450 enzyme. |
Mineral absorption/transport disorder [5C64]
|
[45] |
| Thalidomide |
DM70BU5
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Thalidomide. |
Multiple myeloma [2A83]
|
[19] |
| Siponimod |
DM2R86O
|
Major |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Siponimod. |
Multiple sclerosis [8A40]
|
[19] |
| Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Fingolimod. |
Multiple sclerosis [8A40]
|
[22] |
| Ozanimod |
DMT6AM2
|
Major |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Ozanimod. |
Multiple sclerosis [8A40]
|
[46] |
| Romidepsin |
DMT5GNL
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Romidepsin. |
Mycosis fungoides [2B01]
|
[21] |
| Dasatinib |
DMJV2EK
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[21] |
| Omacetaxine mepesuccinate |
DMPU2WX
|
Moderate |
Additive myelosuppressive effects by the combination of Flutamide and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[47] |
| Promethazine |
DM6I5GR
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Promethazine. |
Nausea/vomiting [MD90]
|
[21] |
| Granisetron |
DMIUW25
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Granisetron. |
Nausea/vomiting [MD90]
|
[21] |
| Dolasetron |
DMMG26Z
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Dolasetron. |
Nausea/vomiting [MD90]
|
[22] |
| Ondansetron |
DMOTQ1I
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ondansetron. |
Nausea/vomiting [MD90]
|
[21] |
| Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[21] |
| Levomethadyl Acetate |
DM06HG5
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Levomethadyl Acetate. |
Opioid use disorder [6C43]
|
[21] |
| Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Lofexidine. |
Opioid use disorder [6C43]
|
[21] |
| Olaparib |
DM8QB1D
|
Moderate |
Increased metabolism of Flutamide caused by Olaparib mediated induction of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[19] |
| Dextropropoxyphene |
DM23HCX
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Dextropropoxyphene. |
Pain [MG30-MG3Z]
|
[21] |
| Prilocaine |
DMI7DZ2
|
Major |
Increased risk of methemoglobinemia by the combination of Flutamide and Prilocaine. |
Pain [MG30-MG3Z]
|
[48] |
| Buprenorphine |
DMPRI8G
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Buprenorphine. |
Pain [MG30-MG3Z]
|
[21] |
| Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[21] |
| Pimavanserin |
DMR7IVC
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Pimavanserin. |
Parkinsonism [8A00]
|
[21] |
| Apomorphine |
DMX38HQ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Apomorphine. |
Parkinsonism [8A00]
|
[21] |
| Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Flutamide caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[49] |
| Famotidine |
DMRL3AB
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Famotidine. |
Peptic ulcer [DA61]
|
[19] |
| Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[50] |
| Lefamulin |
DME6G97
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Lefamulin. |
Pneumonia [CA40]
|
[51] |
| Ritodrine |
DM4V6RL
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Ritodrine. |
Preterm labour/delivery [JB00]
|
[25] |
| Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
| Fluphenazine |
DMIT8LX
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Fluphenazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
| Triflupromazine |
DMKFQJP
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Triflupromazine. |
Psychotic disorder [6A20-6A25]
|
[21] |
| Gatifloxacin |
DMSL679
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[52] |
| Leflunomide |
DMR8ONJ
|
Major |
Increased risk of hepatotoxicity by the combination of Flutamide and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[22] |
| Quetiapine |
DM1N62C
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Quetiapine. |
Schizophrenia [6A20]
|
[21] |
| Mesoridazine |
DM2ZGAN
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Mesoridazine. |
Schizophrenia [6A20]
|
[22] |
| Thioridazine |
DM35M8J
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Thioridazine. |
Schizophrenia [6A20]
|
[22] |
| Aripiprazole |
DM3NUMH
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Aripiprazole. |
Schizophrenia [6A20]
|
[19] |
| Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Iloperidone. |
Schizophrenia [6A20]
|
[22] |
| Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Paliperidone. |
Schizophrenia [6A20]
|
[21] |
| Haloperidol |
DM96SE0
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Haloperidol. |
Schizophrenia [6A20]
|
[22] |
| Perphenazine |
DMA4MRX
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Perphenazine. |
Schizophrenia [6A20]
|
[21] |
| Trifluoperazine |
DMKBYWI
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Trifluoperazine. |
Schizophrenia [6A20]
|
[21] |
| Risperidone |
DMN6DXL
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Risperidone. |
Schizophrenia [6A20]
|
[21] |
| Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Amisulpride. |
Schizophrenia [6A20]
|
[53] |
| Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Asenapine. |
Schizophrenia [6A20]
|
[21] |
| Pimozide |
DMW83TP
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Pimozide. |
Schizophrenia [6A20]
|
[21] |
| Vardenafil |
DMTBGW8
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Vardenafil. |
Sexual dysfunction [HA00-HA01]
|
[21] |
| Trabectedin |
DMG3Y89
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[21] |
| LEE011 |
DMMX75K
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[22] |
| Doxorubicin |
DMVP5YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[21] |
| Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Pitolisant. |
Somnolence [MG42]
|
[21] |
| Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[21] |
| Naltrexone |
DMUL45H
|
Moderate |
Increased risk of hepatotoxicity by the combination of Flutamide and Naltrexone. |
Substance abuse [6C40]
|
[54] |
| Warfarin |
DMJYCVW
|
Moderate |
Increased risk of bleeding by the combination of Flutamide and Warfarin. |
Supraventricular tachyarrhythmia [BC81]
|
[30] |
| Adenosine |
DMM2NSK
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Flutamide and Adenosine. |
Supraventricular tachyarrhythmia [BC81]
|
[22] |
| Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Lenvatinib. |
Thyroid cancer [2D10]
|
[21] |
| Cabozantinib |
DMIYDT4
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Cabozantinib. |
Thyroid cancer [2D10]
|
[21] |
| Papaverine |
DMCA9QP
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Papaverine. |
Tonus and reflex abnormality [MB47]
|
[55] |
| Tizanidine |
DMR2IQ4
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Tizanidine. |
Tonus and reflex abnormality [MB47]
|
[21] |
| Tacrolimus |
DMZ7XNQ
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Tacrolimus. |
Transplant rejection [NE84]
|
[21] |
| Astemizole |
DM2HN6Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Astemizole. |
Vasomotor/allergic rhinitis [CA08]
|
[21] |
| Trimeprazine |
DMEMV9D
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Trimeprazine. |
Vasomotor/allergic rhinitis [CA08]
|
[21] |
| Procainamide |
DMNMXR8
|
Major |
Increased risk of prolong QT interval by the combination of Flutamide and Procainamide. |
Ventricular tachyarrhythmia [BC71]
|
[22] |
| Propafenone |
DMPIBJK
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Propafenone. |
Ventricular tachyarrhythmia [BC71]
|
[21] |
| Flecainide |
DMSQDLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Flutamide and Flecainide. |
Ventricular tachyarrhythmia [BC71]
|
[21] |
| ----------- |
|
|
|
|
|
